What is the official website of Jubilant Radiopharma ?

The official website of Jubilant Radiopharma is http://www.jubilantradiopharma.com.

What is Jubilant Radiopharma's cybersecurity risk score?

Jubilant Radiopharma has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Jubilant Radiopharma experienced?

According to Rankiteo, Jubilant Radiopharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Jubilant Radiopharma been affected by any supply chain cyber incidents ?

According to Rankiteo, Jubilant Radiopharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Jubilant Radiopharma have SOC 2 Type 1 certification ?

According to Rankiteo, Jubilant Radiopharma is not certified under SOC 2 Type 1.

Does Jubilant Radiopharma have SOC 2 Type 2 certification ?

According to Rankiteo, Jubilant Radiopharma does not hold a SOC 2 Type 2 certification.

Does Jubilant Radiopharma comply with GDPR ?

According to Rankiteo, Jubilant Radiopharma is not listed as GDPR compliant.

Does Jubilant Radiopharma have PCI DSS certification ?

According to Rankiteo, Jubilant Radiopharma does not currently maintain PCI DSS compliance.

Does Jubilant Radiopharma comply with HIPAA ?

According to Rankiteo, Jubilant Radiopharma is not compliant with HIPAA regulations.

Does Jubilant Radiopharma have ISO 27001 certification ?

According to Rankiteo,Jubilant Radiopharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Jubilant Radiopharma operate in ?

Jubilant Radiopharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Jubilant Radiopharma have ?

Jubilant Radiopharma employs approximately 585 people worldwide.

Does Jubilant Radiopharma own any subsidiaries ?

Jubilant Radiopharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does Jubilant Radiopharma have ?

Jubilant Radiopharma's official LinkedIn profile has approximately 23,155 followers.

Does Jubilant Radiopharma have a Crunchbase profile ?

No, Jubilant Radiopharma does not have a profile on Crunchbase.

Does Jubilant Radiopharma have a LinkedIn profile ?

Yes, Jubilant Radiopharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/jubilant-radiopharma.

How many cybersecurity incidents has Jubilant Radiopharma experienced ?

As of October 17, 2026, Rankiteo reports that Jubilant Radiopharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does Jubilant Radiopharma have ?

Jubilant Radiopharma has an estimated 5,773 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Jubilant Radiopharma

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Jubilant Radiopharma Vendor Cyber Rating & Cyber Score

jubilantradiopharma.com

Add Your Compliance Badge

Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.

Jubilant Radiopharma

Jubilant Radiopharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Jubilant Radiopharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Jubilant Radiopharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Jubilant Radiopharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Jubilant Radiopharma in 2026.

Incident Types Jubilant Radiopharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Jubilant Radiopharma in 2026.

Incident History - Jubilant Radiopharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Jubilant Radiopharma Subsidiaries

Jubilant Radiopharma

Pharmaceutical Manufacturing

Website: http://www.jubilantradiopharma.com

Company Size: 585

Jubilant Pharmova LimitedPharmaceutical Manufacturing

Jubilant Life Sciences Alumni NetworkPharmaceutical Manufacturing

Jubilant Biosys LimitedResearch

Jubilant Chemsys -> Jubilant Biosys LimitedPharmaceutical Manufacturing

Jubilant Generics LimitedPharmaceutical Manufacturing

Jubilant Pharma LimitedPharmaceutical Manufacturing

Jubilant HollisterStier CMOPharmaceutical Manufacturing

Sterile Ophthalmics & OticsPackaging & Containers

Non-Sterile Topicals and LiquidsPharmaceutical Manufacturing

High Speed Ampoule FillingPharmaceutical Manufacturing

Jubilant Therapeutics IncBiotechnology

Jubilant Cadista PharmaceuticalsPharmaceutical Manufacturing

HollisterStier AllergyPharmaceutical Manufacturing

Loading…

Jubilant Radiopharma Similar Companies

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Medical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

Jubilant Radiopharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 31, 2025 08:00 AM

Jubilant Pharmova Q3 result: Profit rises 51% to Rs 101 cr on strong demand

Revenue rose 9 per cent to Rs 1814 crore, lifted by the radiopharma segment's nearly 12 per cent growth this quarter.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-89096

SUMMARY

A flaw was found in nfs-utils. An unauthenticated remote attacker can trigger a Denial of Service (DoS) by sending repeated state notification requests to an exposed rpc.statd service. The service fails to properly release memory allocated during callback processing, leading to continuous memory growth. Sustained requests can exhaust system resources, eventually causing the service to degrade or crash.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-89088

SUMMARY

A flaw was found in parted. A heap-based buffer overflow exists in libparted's file system resizing logic when handling FAT16 volumes. By convincing a user or administrator to resize a specially crafted FAT16 file system image with malformed directory metadata, an attacker can trigger an oversized read into a fixed-size memory buffer. This issue causes memory corruption, resulting in an application crash and a denial of service (DoS).

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-89085

SUMMARY

A flaw was found in parted. A heap-based buffer overflow can occur when processing a specially crafted FAT32 filesystem due to an integer calculation error during buffer allocation. A local attacker could exploit this by enticing a user or automated service to open a malicious filesystem image, resulting in an application crash leading to a Denial of Service (DoS) or potential memory corruption.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 6.6)

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

1.8

REFERENCES

CVE-2026-17591

SUMMARY

A flaw was found in libarchive. An attacker can cause a Denial of Service (DoS) or potential information disclosure due to a use-after-free vulnerability, which occurs when a program reads memory that has already been released. This issue arises when the archive_entry_copy_mac_metadata() function deallocates an internal buffer before completing a data copy. An attacker who can supply input to an application utilizing this function can trigger the flaw to crash the application or read uninitialized memory data.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 3.6)

cvss3

Base Score: 3.6

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:R/S:U/C:L/I:N/A:L

Impact Score

2.5

Exploitability

REFERENCES

CVE-2026-111802

SUMMARY

A flaw was found in Nautilus. When a removable drive or disk image is unmounted or ejected, Nautilus prompts the user to empty the trash without verifying whether the trash directory paths are symbolic links. An attacker can exploit this flaw by tricking a user into mounting a crafted storage volume and confirming the prompt to empty the trash, leading to the arbitrary deletion of files accessible to that user.

Published

Date2026-10-16

Updated

Date2026-10-16

RISK INFORMATION (Score: 6.6)

cvss3

Base Score: 6.6

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:R/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

1.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Jubilant Radiopharma Vendor Cyber Rating & Cyber Score

Jubilant Radiopharma A.I CyberSecurity Scoring

Jubilant Radiopharma CyberSecurity News & History

Jubilant Radiopharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Jubilant Radiopharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Jubilant Radiopharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Jubilant Radiopharma (X = Date, Y = Severity)

Jubilant Radiopharma Subsidiaries

Jubilant Radiopharma

Jubilant Radiopharma Similar Companies

Lupin

Merck

MSD

Intas Pharmaceuticals

Fresenius Kabi

UCB

AbbVie

Servier

Alembic Pharmaceuticals Limited

Jubilant Radiopharma CyberSecurity News

Jubilant Pharmova Q3 result: Profit rises 51% to Rs 101 cr on strong demand

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Jubilant Radiopharma CyberSecurity News & History

Jubilant Radiopharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Jubilant Radiopharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Jubilant Radiopharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Jubilant Radiopharma (X = Date, Y = Severity)

Jubilant Radiopharma Subsidiaries

Jubilant Radiopharma

Jubilant Radiopharma Similar Companies

Lupin

Merck

MSD

Intas Pharmaceuticals

Fresenius Kabi

UCB

AbbVie

Servier

Alembic Pharmaceuticals Limited

Jubilant Radiopharma CyberSecurity News

Jubilant Pharmova Q3 result: Profit rises 51% to Rs 101 cr on strong demand

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo